<?xml version='1.0' encoding='utf-8'?>
<document id="29804905"><sentence text="Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study."><entity charOffset="0-9" id="DDI-PubMed.29804905.s1.e0" text="Tucatinib" /><entity charOffset="15-27" id="DDI-PubMed.29804905.s1.e1" text="capecitabine" /><entity charOffset="32-43" id="DDI-PubMed.29804905.s1.e2" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.29804905.s1.e0" e2="DDI-PubMed.29804905.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s1.e0" e2="DDI-PubMed.29804905.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s1.e0" e2="DDI-PubMed.29804905.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s1.e1" e2="DDI-PubMed.29804905.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s1.e1" e2="DDI-PubMed.29804905.s1.e2" /></sentence><sentence text="Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on currently available therapies"><entity charOffset="0-9" id="DDI-PubMed.29804905.s2.e0" text="Tucatinib" /><entity charOffset="46-54" id="DDI-PubMed.29804905.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29804905.s2.e0" e2="DDI-PubMed.29804905.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s2.e0" e2="DDI-PubMed.29804905.s2.e1" /></sentence><sentence text=" We aimed to determine the recommended phase 2 dose, safety, pharmacokinetics, and preliminary activity of tucatinib in combination with capecitabine or trastuzumab in patients with HER2-positive breast cancer with or without brain metastases"><entity charOffset="107-116" id="DDI-PubMed.29804905.s3.e0" text="tucatinib" /><entity charOffset="137-149" id="DDI-PubMed.29804905.s3.e1" text="capecitabine" /><entity charOffset="153-164" id="DDI-PubMed.29804905.s3.e2" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.29804905.s3.e0" e2="DDI-PubMed.29804905.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s3.e0" e2="DDI-PubMed.29804905.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s3.e0" e2="DDI-PubMed.29804905.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s3.e1" e2="DDI-PubMed.29804905.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s3.e1" e2="DDI-PubMed.29804905.s3.e2" /></sentence><sentence text="" /><sentence text="In this non-randomised, open-label, phase 1b trial done in five sites in the USA, we recruited patients aged 18 years or older with HER2-positive progressive breast cancer who had been previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine"><entity charOffset="222-232" id="DDI-PubMed.29804905.s5.e0" text="pertuzumab" /></sentence><sentence text=" Eligible patients required HER2-positivity assessed locally, evaluable lesions as defined per Response Evaluation Criteria in Solid Tumors, version 1" /><sentence text="1, and an Eastern Cooperative Oncology Group performance status of 0 or 1" /><sentence text=" Tucatinib was administered twice a day in conjunction with capecitabine 1000 mg/m2 orally twice a day for 14 days of a 21-day cycle, trastuzumab 6 mg/kg intravenously once every 21 days, or both"><entity charOffset="1-10" id="DDI-PubMed.29804905.s8.e0" text="Tucatinib" /><entity charOffset="60-72" id="DDI-PubMed.29804905.s8.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.29804905.s8.e0" e2="DDI-PubMed.29804905.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s8.e0" e2="DDI-PubMed.29804905.s8.e1" /></sentence><sentence text=" A modified 3 + 3 dose-escalation design was used to determine the recommended phase 2 dose, starting with tucatinib in combination with capecitabine or trastuzumab, and subsequently evaluating the triplet combination"><entity charOffset="107-116" id="DDI-PubMed.29804905.s9.e0" text="tucatinib" /><entity charOffset="137-149" id="DDI-PubMed.29804905.s9.e1" text="capecitabine" /><entity charOffset="153-164" id="DDI-PubMed.29804905.s9.e2" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.29804905.s9.e0" e2="DDI-PubMed.29804905.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s9.e0" e2="DDI-PubMed.29804905.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s9.e0" e2="DDI-PubMed.29804905.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s9.e1" e2="DDI-PubMed.29804905.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s9.e1" e2="DDI-PubMed.29804905.s9.e2" /></sentence><sentence text=" The primary endpoint was to establish the maximum tolerated dose and recommended phase 2 dose of tucatinib, evaluated by toxicity assessments"><entity charOffset="98-107" id="DDI-PubMed.29804905.s10.e0" text="tucatinib" /></sentence><sentence text=" Efficacy was assessed in all patients by contrast CT of the body" /><sentence text=" Analyses included all patients who had received at least one dose of study treatment" /><sentence text=" The study is registered with ClinicalTrials" /><sentence text="gov, number NCT02025192" /><sentence text="" /><sentence text="Between Jan 15, 2014, and Dec 15, 2015, 60 patients were enrolled and treated" /><sentence text=" The current report is from mature data as of June 30, 2017" /><sentence text=" The tucatinib recommended phase 2 dose was determined to be 300 mg orally twice a day, equivalent to single-agent maximum tolerated dose"><entity charOffset="5-14" id="DDI-PubMed.29804905.s18.e0" text="tucatinib" /></sentence><sentence text=" Pharmacokinetic analysis showed that there was no drug-drug interaction with capecitabine"><entity charOffset="78-90" id="DDI-PubMed.29804905.s19.e0" text="capecitabine" /></sentence><sentence text=" Adverse events seen at the recommended phase 2 dose regardless of causality, grade, and treatment group included diarrhoea (35 [67%] of 52 patients), nausea (31 [60%] patients), palmar-plantar erythrodysaesthesia syndrome (23 [44%] patients), fatigue (20 [38%] patients), and vomiting (20 [38%] patients)" /><sentence text=" In all patients, treatment-related toxicities of grade 3 and worse included fatigue (five [8%] patients), diarrhoea (four [7%] patients), and palmar-plantar erythrodysaesthesia (four [7%] patients)" /><sentence text=" No treatment-related deaths were reported" /><sentence text=" The proportion of patients with measurable disease achieving objective response was 83% (five of six patients) in the combination of tucatinib with capecitabine, 40% (six of 15 patients) in the combination of tucatinib with trastuzumab, and 61% (14 of 23 patients) in the combination of tucatinib with both capecitabine and trastuzumab"><entity charOffset="134-143" id="DDI-PubMed.29804905.s23.e0" text="tucatinib" /><entity charOffset="149-161" id="DDI-PubMed.29804905.s23.e1" text="capecitabine" /><entity charOffset="210-219" id="DDI-PubMed.29804905.s23.e2" text="tucatinib" /><entity charOffset="288-297" id="DDI-PubMed.29804905.s23.e3" text="tucatinib" /><entity charOffset="308-320" id="DDI-PubMed.29804905.s23.e4" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e0" e2="DDI-PubMed.29804905.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e0" e2="DDI-PubMed.29804905.s23.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e0" e2="DDI-PubMed.29804905.s23.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e0" e2="DDI-PubMed.29804905.s23.e3" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e0" e2="DDI-PubMed.29804905.s23.e4" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e1" e2="DDI-PubMed.29804905.s23.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e1" e2="DDI-PubMed.29804905.s23.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e1" e2="DDI-PubMed.29804905.s23.e3" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e1" e2="DDI-PubMed.29804905.s23.e4" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e2" e2="DDI-PubMed.29804905.s23.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e2" e2="DDI-PubMed.29804905.s23.e3" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e2" e2="DDI-PubMed.29804905.s23.e4" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e3" e2="DDI-PubMed.29804905.s23.e3" /><pair ddi="false" e1="DDI-PubMed.29804905.s23.e3" e2="DDI-PubMed.29804905.s23.e4" /></sentence><sentence text="" /><sentence text="Tucatinib in combination with capecitabine and trastuzumab had acceptable toxicity and showed preliminary anti-tumour activity"><entity charOffset="0-9" id="DDI-PubMed.29804905.s25.e0" text="Tucatinib" /><entity charOffset="30-42" id="DDI-PubMed.29804905.s25.e1" text="capecitabine" /><entity charOffset="47-58" id="DDI-PubMed.29804905.s25.e2" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.29804905.s25.e0" e2="DDI-PubMed.29804905.s25.e0" /><pair ddi="false" e1="DDI-PubMed.29804905.s25.e0" e2="DDI-PubMed.29804905.s25.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s25.e0" e2="DDI-PubMed.29804905.s25.e2" /><pair ddi="false" e1="DDI-PubMed.29804905.s25.e1" e2="DDI-PubMed.29804905.s25.e1" /><pair ddi="false" e1="DDI-PubMed.29804905.s25.e1" e2="DDI-PubMed.29804905.s25.e2" /></sentence><sentence text=" Validation of the current study results will be determined in the double-blinded randomised study, HER2CLIMB (ONT-380-206; NCT02614794)" /><sentence text="" /><sentence text="Cascadian Therapeutics, a wholly owned subsidiary of Seattle Genetics" /><sentence text="" /></document>